Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9763870 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL1660811 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763539 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763505 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL5597970 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763877 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4901679 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4020685 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL14544900 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9274196 | 0.91 | HMGCR (0.52) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5004747-A | Isoquinolinones | MAY & BAKER LIMITED (GB) | 1991-04-02 | — | — | US | claimed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2011-04-28 | — | — | US | disclosed |
| US-5004747-A | Isoquinolinones | MAY & BAKER LIMITED (GB) | 1991-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | HMGCR 137/4885 |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | HMGCR 69/4885 |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | HMGCR, HMGB2, GRHPR | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.